首页> 美国卫生研究院文献>other >Is Tamoxifen Use a Factor Affecting Continence in Breast Cancer Patients?
【2h】

Is Tamoxifen Use a Factor Affecting Continence in Breast Cancer Patients?

机译:他莫昔芬是否会影响乳腺癌患者的节制?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Introduction: Tamoxifen treatment has been shown to reduce the recurrence and mortality rates in hormone receptor-positive breast cancers independent from chemotherapy. This benefit increases with the prolongation of the use of tamoxifen but with increasing side effects. In this study, we aim to evaluate the presence of urogenital symptoms in breast cancer patients on tamoxifen and compare them with those who are not on any hormonotherapy.Materials and methods: This study was performed on patients diagnosed as early-stage breast cancer. The study group consisted of hormone receptor-positive patients given tamoxifen as adjuvant hormonal therapy. The control group consisted of breast cancer patients who had no hormonotherapy. Patients with a complaint of urinary incontinence with onset after tamoxifen usage were evaluated with Urogenital Distress Inventory Short Form (UDI-6), Incontinence Impact Questionnaire Short Form (IIQ-7) and Incontinence Quality of Life Questionnaire (I-QOL).Results: A total of 137 early-stage breast cancer patients were included in this study; 74 estrogen receptor-positive patients on tamoxifen therapy (study group) and 63 hormone receptor-negative patients with no hormonotherapy (control group). The median age was 44 (30-65) years for tamoxifen users and 49 (27-64) years for the control group. The stages of the patients were similar for both groups. 78.4% of the women in the tamoxifen group and 49.2% in the control group were in the premenopausal period. The groups were similar in regard to body mass index and parity. The complaint of urinary incontinence was more frequent in the study group compared to controls (39 (52.7%) vs. 5 (7.9%)). Women with the complaint of urinary incontinence were evaluated with self-reported UDI-6, IIQ-7 and I-QOL forms and the scores were similar for both study and control groups. A statistically significant relation was observed between cigarette smoking and the presence of urinary incontinence. The percentages of smokers were 50% of those with incontinence and 24.7% of those without incontinence.Conclusion: Urinary incontinence is positively correlated with tamoxifen usage in early-stage breast cancer patients.
机译:简介:已经证明他莫昔芬治疗可降低激素受体阳性乳腺癌的复发率和死亡率,而与化疗无关。随着他莫昔芬使用时间的延长,该益处增加,但副作用增加。在这项研究中,我们旨在评估使用他莫昔芬的乳腺癌患者中泌尿生殖系统症状的存在,并将其与未接受任何激素疗法的患者进行比较。材料与方法:这项研究是针对诊断为早期乳腺癌的患者进行的。研究组由接受他莫昔芬辅助激素治疗的激素受体阳性患者组成。对照组由没有激素疗法的乳腺癌患者组成。使用他莫昔芬后因尿失禁而发作的主诉患者使用泌尿生殖器窘迫库存简表(UDI-6),失禁影响问卷调查表(IIQ-7)和失禁生活质量问卷(I-QOL)进行了评估。这项研究总共包括了137名早期乳腺癌患者。 74例接受他莫昔芬治疗的雌激素受体阳性患者(研究组)和63例未经激素治疗的激素受体阴性患者(对照组)。他莫昔芬使用者的中位年龄为44(30-65)岁,对照组为49(27-64)岁。两组患者的分期相似。他莫昔芬组的妇女的78.4%和对照组的49.2%的妇女处于绝经前期。两组在体重指数和均等方面相似。与对照组相比,研究组尿失禁的投诉率更高(39(52.7%)对5(7.9%))。用自我报告的UDI-6,IIQ-7和I-QOL表格评估了患有尿失禁的女性,研究组和对照组的得分相似。吸烟与尿失禁之间存在统计学意义的相关性。结论:尿失禁与他莫昔芬在早期乳腺癌患者中的使用呈正相关。吸烟率是尿失禁的50%,尿失禁的24.7%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号